Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > Pretty wild
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(88)
•••
Comment by SABBOBCATon Dec 06, 2022 10:51am
81 Views
Post# 35153315

RE:Pretty wild

RE:Pretty wildI saw you take my pilot analogy and tag them I. It on Linkedin hahaha that's awesome 

Bucknelly21 wrote:

So i post alot on linkden regarding thera mainly because paul seems to spend alot of time on there. So anyway i posted how disrespectful it was to shareholders to not have a call explaining implications ect of the recent pr. I had multiple employees like the comment including 1 board member andrew molson. These guys have moved from bad to completely disfunctional in my opinion. I was a huge fan of these guys years ago but they have completely eroded that and turned it into what it is today from lack of adaptation, competence and arrogance. Paul is not the right guy, elif the ir person is a weird lady and phillipe might be good with numbers but has no idea or is just too stubborn to realize that his methods are completely awful. Regardless im watching from the sidelines as i cant let this management jeopardize my investment anymore 

 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities